OncoCyte
2009
FOUNDED
PUBLIC
STATUS
11-20
EMPLOYEES
OCX
STOCK SYMBOL
3
INVESTMENTS
$3.02
SHARE PRICE
(As of Friday Closing)
Description
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, the company also developing screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through United States and it earns revenue from the sale of diagnostic tests.
Primary Industry
Diagnostic Equipment
Other Industries
Discovery Tools (Healthcare)
Stock Exchange
ASE
Primary Office
- 1010 Atlantic Avenue
- Suite 102
- Alameda, CA 94501
- United States
+1 (510) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore OncoCyte’s full profile, request a free trial.
OncoCyte Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $1.50 - $6.92 | $172M | $2.98 | -$0.40 | 277K | 60.6M |
OncoCyte Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 73,913 | 46,500 | 136,710 | 187,694 |
| Revenue | 0 | 0 | 0 | |
| EBITDA | (18,805) | (14,979) | (18,578) | (10,753) |
| Net Income | (18,971) | (15,754) | (19,375) | (11,168) |
| Total Assets | 32,770 | 9,518 | 10,216 | 14,447 |
| Total Debt | 1,222 | 1,719 | 2,497 | 512 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
OncoCyte Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore OncoCyte‘s full profile, request access.
Request full access to PitchBookOncoCyte Competitors (42)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nucleix | Venture Capital-Backed | Rehovot, Israel | 00 | 000.00 | 0000000000 | 000.00 |
| 00000000000 000000 | Venture Capital-Backed | Birmingham, AL | 00 | 00.000 | 0000000000 0 | 00.000 |
| 0000000000 | Venture Capital-Backed | Pittsburgh, PA | 0 | 00.00 | 00000000000 | 00.00 |
| 000000 00000000000 | Venture Capital-Backed | Pleasanton, CA | 000000&0 | |||
| 00000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000000 | 00000 |
OncoCyte Acquisitions (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 00000000 | 10-Jan-2020 | 000000000000000000 | 0000 | Biotechnology | 000000 000000 00 |
| 00000 00000000 | 05-Sep-2019 | 000000000000000000 | 0000 | Diagnostic Equipment | |
| Cell Targeting | 28-Jan-2011 | Merger/Acquisition | 00.00 | Biotechnology |
OncoCyte Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore OncoCyte‘s full profile, request access.
Request full access to PitchBookOncoCyte Executive Team (7)
2 Former Executives
You’re viewing 5 of 7 executives. Get the full list »OncoCyte Board Members (9)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Adi Mohanty | Lineage Cell Therapeutics | Board Member | 000 0000 | |
| Alfred Kingsley JD | Self | Board Member | 000 0000 | |
| Andrew Last Ph.D | Self | Board Member | 000 0000 | |
| Andy Arno | OncoCyte | Board Member | 000 0000 | |
| Cavan Redmond | OncoCyte | Chairman & Board Member | 000 0000 |
2 Former Board Members
You’re viewing 5 of 9 board members. Get the full list »